A solid majority of respondents said vertical integration among providers is the consolidation trend that is most likely to accelerate this year.
Healthcare used to be a fairly decentralized sector of the economy with plenty of local doctors and hospitals. Large insurers such as UnitedHealth Group and Aetna are not new, but now they not just insurers. UnitedHealth Group owns Optum, an increasingly large “health services company,” and Aetna is part of CVS Health.
The Managed Healthcare Executive® State of the Industry survey asked which of the many consolidation trends in the sector is mostly to accelerate this year. A solid majority (58%) of the roughly 450 respondents picked vertical integration of provider organizations, such as hospitals and physician groups.
Only a small group (20%) indicated that they believed horizontal consolidation of provider organizations — hospitals combining with other hospitals, for example — would speed up this year. Even smaller groups of respondents (14% and 7%, respectively) picked horizonal and vertical consolidation of payers as likely to be speed up this year.
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Conversations with Perry and Friends: Saar Mahna, J.D., MBA
July 7th 2025Perry Cohen, Pharm.D., a longtime member of the Managed Healthcare Executive editorial advisory board, is host of the "Conversations with Perry and Friends" podcast. In this episode, Cohen speaks with Saar Mahna, J.D., MBA, CEO and founder of Banjo Health, an artificial intelligence company focused on prior authorization.
Listen
PBM-Offered Genomics Testing Could Reshape Prescribing of Medications
July 25th 2025Two PBMs, True Rx Health Strategies and Capital Rx, are using pharmacogenomics — how a person’s DNA affects their response to medications — to reduce the trial-and-error of prescribing medications, saving employers and patients time and money.
Read More
Conversations With Perry and Friends: Paul Fronstin, Ph.D.
May 9th 2025Perry Cohen, Pharm.D., a longtime member of the Managed Healthcare Executive editorial advisory board, is host of the Conversations with Perry and Friends podcast. In this episode, his guest is Paul Fronstin, Ph.D., director of health benefits research at the Employee Benefit Research Institute.
Listen
FDA Accepts Tabelecleucel BLA; Priority Review Granted for Post-Transplant Disease Therapy
July 24th 2025The FDA has accepted the resubmitted BLA for tabelecleucel (tab-cel), intended for the treatment of Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+ PTLD).
Read More